Corvus Pharmaceuticals, Inc. (CRVS): Stock Offering News

CRVS – Commences an underwritten public offering of up to $50 mln shares of its common stock.


Key Facts Surrounding This News Item


  • CRVS had a POWR Rating of D (Sell) coming into today.
  • CRVS was 9.05% above its 10-Day Moving Average coming into today.
  • CRVS was 10.26% above its 20-Day Moving Average coming into today.
  • CRVS was -2.31% below its 50-Day Moving Average coming into today.
  • CRVS was -17.08% below its 100-Day Moving Average coming into today.
  • CRVS was -24.89% below its 200-Day Moving Average coming into today.
  • CRVS had returned -12.74% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About Corvus Pharmaceuticals, Inc. (CRVS)


Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California. View our full CRVS ticker page with ratings, news, and more.

CRVS at a Glance

CRVS Current POWR Rating™
Overall POWR Rating™
CRVS Current Price $5.26 4.01%
More CRVS Ratings, Data, and News

CRVS Price Reaction

The day of this event (Mar. 7, 2018)
CRVS Closing Price$9.52 5.31%
CRVS Volume50,900
56.37% from avg
Leading up to this event
CRVS 1-mo return10.38%
After this event
CRVS 1-day return7.19%
CRVS 3-day return7.57%
CRVS 5-day return14.23%

CRVS Price Chart


The Top Stocks For 2019

More Corvus Pharmaceuticals, Inc. (CRVS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CRVS News
Page generated in 0.9242 seconds.